House Heads for Thursday Vote on ObamaCare Repeal

The House will vote on the GOP's ObamaCare repeal and replace plan Thursday after nearly seven years of trying to take down the healthcare law.

Read More

Ricardo Lara Enters Race for California State Insurance Commissioner

Today State Senator Ricardo Lara, who recently co-introduced Californians for a Healthy California Act (SB 562), which amounts to single-payer healthcare for the state, announced that he will be running to serve as California's State Insurance Commissioner - a statewide elected office dedicated to protecting consumers, enforcing all insurance regulations, and safeguarding Californians' economic and health security.

Read More

Heads Up, Pharma. Trump’s Pushing GOP to Put “Competitive Bidding” on Drugs in Healthcare Bill

How would a “competitive bidding process” for drugs work? We may soon find out, if President Donald Trump gets his way with the Republican healthcare bill.

Read More

Conservative House Republicans Say They Have Enough Votes to Stop Health Care Bill

Conservative House Republicans said Monday night that they have enough votes to block the GOP’s legislation to dismantle the Affordable Care Act, as House leaders proposed changes to the bill in a late effort to draw support.

Read More

Understanding The Hidden Villain of Big Pharma: Pharmacy Benefit Managers

In the past few months, four bills have been introduced in Congress calling for transparency in prescription drug pricing. These bills—HR 1038, HR 1316, S.3308 and, earlier this week, one called C-THRU—largely concern pharmacy benefit managers (PBMs), a heretofore largely unrecognized component of the pharmaceutical industry.

Read More

Marathon, Under Heavy Fire for Emflaza Pricing, Makes Surprise Deal to Sell Drug for $140M-Plus

Marathon Pharmaceuticals is in plenty of hot water after its brazen $89,000 pricing on the old-turned-new Duchenne muscular dystrophy drug Emflaza—a decades-old product available overseas for $1,000 per year. Now, it’s scored a quick payoff by selling the med to PTC Therapeutics in a deal potentially worth more than $190 million.

Read More
arrowcaret-downclosefacebook-squarehamburgerinstagram-squarelinkedin-squarepauseplaytwitter-squareyoutube-square